- Home
- SGRY
as 12-20-2024 4:00pm EST
Surgery Partners Inc is a healthcare services company with an integrated outpatient delivery model focused on providing quality, cost-effective solutions for surgical and related ancillary care in support of both patients and physicians. It operates in two segments: Surgical Facility Services and Ancillary Services out of which the Surgical Facility Services segment accounts for the majority of revenue.
| Founded: | 2004 | Country: | United States |
| Employees: | N/A | City: | BRENTWOOD |
| Market Cap: | 2.7B | IPO Year: | 2015 |
| Target Price: | $37.38 | AVG Volume (30 days): | 1.3M |
| Analyst Decision: | Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.48 | EPS Growth: | N/A |
| 52 Week Low/High: | $19.50 - $35.30 | Next Earning Date: | 11-12-2024 |
| Revenue: | $2,985,300,000 | Revenue Growth: | 9.96% |
| Revenue Growth (this year): | 14.46% | Revenue Growth (next year): | 9.94% |
Latest Surgery Partners Inc. News
SGRY Breaking Stock News: Dive into SGRY Ticker-Specific Updates for Smart Investing
MT Newswires
19 days ago
JPMorgan Adjusts Surgery Partners Price Target to $28 From $38, Maintains Neutral Rating
MT Newswires
a month ago
RBC Cuts Price Target on Surgery Partners to $35 From $49, Keeps Outperform Rating
Simply Wall St.
a month ago
Surgery Partners Third Quarter 2024 Earnings: EPS Misses Expectations
MT Newswires
a month ago
Macquarie Adjusts Surgery Partners Price Target to $34 From $35, Maintains Outperform Rating
GuruFocus.com
a month ago
Surgery Partners Inc (SGRY) Q3 2024 Earnings Call Highlights: Robust Revenue Growth and ...
Zacks
a month ago
Surgery Partners (SGRY) Misses Q3 Earnings Estimates
MT Newswires
a month ago
Surgery Partners' Q3 Adjusted Net Income Unchanged, Revenue Rises
Associated Press Finance
a month ago
Surgery Partners: Q3 Earnings Snapshot
Compare SGRY vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SGRY Surgery Partners Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.